Tag - AURA

Developments

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Aura Biosciences (NASDAQ:AURA) has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal...

September 12, 2024

Markets

Analysts start AURA Biosciences at OP, buy

Analysts for SVB Leerink and BTIG initiated coverage of AURA Biosciences (NASDAQ:AURA) with “outperform” and “buy” ratings and price targets of $40 and $38, respectively. The stock closed at $19.82 on Nov. 22. AURA is a...

November 23, 2021

Feature

Verisante to seek FDA approval of Aura skin cancer device

By Len Zehr In addition to ramping up distribution of its Aura non-invasive skin cancer detection device this year, Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) is preparing the process to seek FDA approval of Aura...

June 11, 2013

Tag - AURA

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Analysts start AURA Biosciences at OP, buy

Verisante to seek FDA approval of Aura skin cancer device

General

More